collaterals at the base of the brain. 12, 13 When identified in the presence of other conditions, the name "moyamoya syndrome" is often applied to distinguish it from the idiopathic, bilateral moyamoya disease. The clinical course of moyamoya syndrome has been well described in other populations; a key feature includes relentless, if unpredictable, disease progression. Progressive stenosis ultimately results in worsening ischemia without surgical revascularization.
14, 15 The understanding of moyamoya syndrome in children with NF1 remains less clear, especially with regard to response and outcome after surgical therapy. In this paper we describe the clinical, radiographic, and angiographic features of moyamoya syndrome associated with NF1 in a series of children who were treated with a standardized method of surgical revascularization-pial synangiosis-to characterize the features of moyamoya syndrome in this population, along with the long-term outcome after surgical treatment.
Methods

Study Population
The study was approved by the Institutional Review Board of Boston Children's Hospital. A computerized search was used to identify all patients younger than 21 years of age with NF1 who were diagnosed with moyamoya syndrome and who underwent surgical revascularization between January 1988 and April 2012 at Boston Children's Hospital. All patients met clinical criteria for NF1, by virtue of at least 2 of the following findings: multiple café-au-lait spots (6 or more > 0.5 cm in diameter if prepubertal, 6 or more > 1.5 cm if postpubertal); 2 or more subcutaneous neurofibromas or 1 plexiform neurofibroma; axillary or inguinal freckling; optic glioma; tibial pseudarthrosis or sphenoid wing dysplasia; 2 or more Lisch nodules; and a first-degree relative with the disorder. 9 
Data Collection
Clinical data were reviewed in detail. Data collection included demographic information, dates of initial imaging that demonstrated the vascular changes and indication for imaging, dates of all procedures/interventions, details of neurological symptoms, examination at presentation and follow-up as well as any prior treatments received (surgery, chemotherapy, and/or radiation therapy for an intracranial lesions). All imaging studies were reviewed, including CT, MRI/MR angiography, and cerebral arteriography. The date of each patient's moyamoya diagnosis was given when it was first diagnosed radiographically. On cerebral angiography, Suzuki stage was determined as a measure of severity of arteriographic disease, ranging from Stage I to VI, with Stage VI being the most severe. 17 Postsurgical collateral vessels were graded according to the method of Matsushima et al. 8 Perioperative, subacute, and delayed complications, as well as long-term clinical and radiographic outcomes, were reviewed. Progression of moyamoya was evaluated by MRI and angiography (whichever modalities were available).
The functional status of each patient was graded according to the mRS: 0 = no symptoms; 1 = minor symptoms not affecting lifestyle; 2 = minor handicap but independent in activities of daily living; 3 = requiring some help with activities of daily living; 4 = requiring substantial help with activities of daily living; 5 = totally dependent. This score was determined by the reported physical examination, clinical description, and patient/parent report of the patient's functional status as relayed through the clinical notes of the neurosurgeon, neurologist, or oncologist.
Data Analysis
Statistical measures including the t-test and Fisher exact test were used where appropriate to evaluate for significant differences. Separate subanalyses were performed to compare patients who received cranial radiation preoperatively to those who did not, to differentiate those who were exposed to a potential environmental "trigger," and to compare patients who were symptomatic with those who were asymptomatic preoperatively.
Results
Patient Demographics and NF1 Clinical Features
A total of 39 patients with NF1 were diagnosed with moyamoya syndrome during the study period (27 female, 12 male, age range 0.2-19.3 years). Of these 39 patients, 32 were treated with pial synangiosis in a total of 52 hemispheres, with each hemisphere counted as a separate operative procedure. The demographic and NF1 characteristics of these patients are detailed in Table 1 . Figure  1 outlines the surgical and nonsurgical management of the patients in the study. Twenty-two of the 32 surgical patients underwent clinical follow-up and 29 of 32 had radiographic follow-up. Most patients who are lost to clinical follow-up are those who are referred to our institution for surgical procedures and therefore follow-up occurs locally. Those patients for whom imaging was not available for review were not included in the longitudinal follow-up because strokes and progression of disease could not be verified. All 32 surgical patients had previously met the criteria for the diagnosis of NF1. Twenty-two (69%) of the 32 patients were female. A subset of patients was referred from outside institutions, therefore the precise time of the NF1 diagnosis and the NF1 clinical features were not available in all patients. The mean age at diagnosis of NF1 in those 21 patients for whom data were available was 2.7 years (median 2 years, range 0.0-12.2 years). For those in whom clinical features were known, all 22 had café-au-lait spots, 16 (84%) of 19 had skin-fold freckling, 12 (60%) of 20 had known cutaneous or subcutaneous neurofibromas, 6 (32%) of 19 had a plexiform neurofibroma, 14 (58%) of 24 had an optic pathway glioma, 2 (11%) of 19 had a bone lesion, 7 (58%) of 12 had Lisch nodules, and 6 (29%) of 21 had a known family history of NF1.
Presentation of Moyamoya
The mean age at radiographic diagnosis of moyamoya was 7.0 years (range 0.2-15.6 years). The mean duration from presentation of moyamoya to surgery was 8.4 months (range 0.6-39.5 months) and the mean age at the time of first surgical treatment was 8.1 years (range 0.5-15.6 years). Eleven patients (34%) were clinically asymptomatic at the time of radiographic diagnosis, while the remaining 21 patients manifested symptoms consistent with cerebral ischemia prior to surgery ( Table 2) . Of these 21 patients who were symptomatic at the time of radiographic diagnosis, 15 experienced TIAs, 14 had prior stokes, and 5 had a history of seizures. Prior to surgical intervention, 25 of 32 patients were noted to have developed neurological symptoms. Only 1 patient presented with intracerebral hemorrhage.
Among the 32 patients who underwent surgical revascularization, 8 (25%) had received prior cranial irradiation (Table 1) . In all cases, radiation was administered for an optic pathway glioma. The average radiation dose was 5209 cGy (range 5000-5400 cGy). Patients who had received cranial irradiation were more likely to have experienced neurological symptoms prior to surgical revascularization. Of the 8 patients who were treated with cranial irradiation preoperatively, 5 (63%) were symptomatic at the time of radiographic diagnosis, and 7 (88%) were symptomatic prior to surgical revascularization. In contrast, in the 24 patients who had not received cranial irradiation, 16 (67%) had neurological symptoms at the time of radiographic diagnosis and 18 (75%) were symptomatic prior to surgery. In addition, patients who had received cranial irradiation subjectively reported more severe neurological symptoms.
Radiographic Presentation and Features
In 32 patients, 52 affected hemispheres were operated on. Preoperative MRI data were available for 30 of 32 patients, involving 48 of 52 affected hemispheres. Digital subtraction angiography data were available for 30 of 32 patients, involving 49 of 52 affected hemispheres ( Table  2 ). The mean Suzuki stage at the time of presentation was 3.2 on the affected side, with a range of 1.0-5.5.
Eighteen patients (56%) demonstrated radiographic evidence of prior infarction in 24 hemispheres (46%). Bilateral disease was present in 20 (62%) of 32 patients. Among those with unilateral disease, the left and right hemispheres were affected in 7 and 5 patients, respectively (Table 2) .
Previous cranial irradiation was associated with worse severity of radiographic disease as compared with patients who did not receive radiation. All patients who underwent radiation treatment had bilateral disease, with 6 of 8 patients exhibiting radiographic evidence of prior stroke at the time of diagnosis. In contrast, in patients who did not receive cranial irradiation, Suzuki stages were lower, with both unilateral disease and radiographic evidence of prior stroke in 12 of 24 patients.
Patients who had experienced no neurological symptoms prior to surgery were more likely to have a lower Suzuki grade at presentation. Moreover, 4 (57%) of these 7 clinically asymptomatic patients demonstrated unilateral disease and only 2 (29%) of 7 patients had radiographic evidence of prior stroke. Of those who were symptomatic prior to surgery, the Suzuki stage was higher, with 8 (32%) of 25 having unilateral disease and 16 (64%) of 25 showing radiographic evidence of prior stroke. Table  3 summarizes the Suzuki stage preoperatively, according to whether the patients were symptomatic or asymptomatic prior to surgery, and whether they had received prior cranial irradiation.
Operative Treatment and Surgical Outcome
All 32 patients in this series underwent a standardized indirect cerebral revascularization procedure to treat 50 of 52 affected hemispheres. 1 These procedures included 14 unilateral and 18 bilateral operations (Table  4) consisting of 51 pial synangioses, 1 attempted superficial temporal artery-middle cerebral artery bypass, 1 dural synangiosis, and 13 involving some form of bur hole placement as an adjunct to revascularization. Five patients had reoperations temporally distinct from the initial surgery. Of these reoperations, 1 was a planned staging of bilateral disease, 2 were for progression of the contralateral hemisphere, and 2 were for revascularization of the previously operated hemisphere as the patients again demonstrated symptoms of chronic ischemia after the initial operation (Table 4) . Current practice for bilateral disease is to perform the operation on both sides during a single anesthesia procedure on the same day if the patient remains stable intraoperatively, rather than staging the operations separately. Our 1 patient with planned staging developed slowing on electroencephalography intraoperatively; therefore, the procedure on the contralateral hemisphere was delayed 3 months to allow for collateral development and to increase safety of the procedure. Mean blood loss was 39 ml/hemisphere (range 10-150 ml). The mean length of stay was 4.6 days (range 3-20 days), which included a scheduled hospital admission on the night prior to surgery for preoperative hydration. Medical management with aspirin was initiated in 30 of 32 patients.
Perioperative Complications
Perioperative complications occurred in 3 different patients, each of whom had ischemic symptoms prior to surgery. The first patient had a history of prior cranial irradiation and experienced the onset of left-sided weakness, increased tone in all extremities, and diminished speech within the first 24 hours postoperatively. Magnetic resonance imaging confirmed bilateral watershed strokes involving extension of a preoperative temporoparietal stroke as well as a new, deeper, left frontal stroke. This patient also experienced a minor postoperative infection-a stitch abscess-requiring intravenous antibiotics without surgical treatment. Three weeks after discharge, her examination demonstrated mild quadriparesis and a partial expressive aphasia.
The second patient with a history of prior cranial irradiation developed abnormal chewing movements, increasing drooling, poor swallowing, slurred speech, and lethargy on postoperative Days 2 and 3. The patient's presentation and CT scan were concerning for bilateral frontal stroke. Electroencephalography demonstrated generalized slowing without epileptiform activity. This patient's symptoms improved. She was discharged on postoperative Day 6.
The third patient, who had not received prior cranial irradiation, experienced a TIA with transient expressive aphasia and left-sided weakness on postoperative Day 2. Imaging did not reveal an acute infarct or intraparenchymal hemorrhage. Symptoms resolved within 24 hours and neurological status returned to the preoperative baseline level. The patient was discharged home on postoperative Day 8. Thus, both documented strokes in the immediate postoperative period occurred in patients who were previously treated with cranial irradiation, and both strokes were detected on MRI. There were no perioperative seizures or deaths in this series (Table 4) .
Clinical Outcome After Hospital Discharge
The average duration of clinical and/or radiographic follow-up was 80.2 months (range 9.4-257 months; n = 30; Table 5 ). Detailed neurological outcomes were available for 22 patients, who were evaluated for clinical improvement, stability, or deterioration using the mRS. At the time of most recent postoperative follow-up, 16 (73%) of 22 were neurologically intact or had minimal neurological deficit (mRS Score 0-1), 6 (27%) evidenced mild neurological deficits (mRS Score 2-3), and none were considered dependent (mRS Score 4-5). In comparison with their preoperative mRS score, 7 (32%) of 22 were improved, 14 (64%) were stable, and 1 (5%) worsened in neurological function. The patient who evidenced worsening of neurological function experienced progression of an optic pathway tumor after radiation treatment and did not experience new ischemic injury. Patients who had been treated with cranial irradiation prior to surgery were more likely to have neurological deficits or to show deterioration in function postoperatively, although tumor-and treatment-related factors may have contributed. During follow-up, 3 (60%) of 5 patients treated with radiation were neurologically intact or had minimal neurological deficit (mRS Score 0-1) compared with 13 (76%) of 17 patients not treated with radiation. Similarly, 1 (20%) of 5 patients treated with radiation was considered dependent (mRS Score 4-5) and experienced deterioration in mRS score postoperatively compared with none of the patients who did not undergo radiation. Although these differences suggest a trend for worse outcome in patients who had received prior radiation, it did not reach statistical significance.
To evaluate the predictive value of preexisting neurological deficits on long-term outcome, we compared available follow-up examinations between patients who had preoperative deficits (n = 17) to patients without deficits (n = 5). Overall, 21 of 22 patients demonstrated stable or improved neurological status. Not surprisingly, patients who manifested neurological deficits before surgery were more likely to continue to manifest symptoms at follow-up, and with more significant neurological disability when compared with the asymptomatic group. Postoperatively, 12 of 17 patients in the symptomatic group were neurologically intact or had minimal neurological deficits (mRS Score 0-1), 5 had mild neurological deficits (mRS Score 2-3), and none were considered dependent (mRS Score 4-5) compared with the asymptomatic group, in which 4 of 5 were intact or had minimal neurological deficits and 1 of 5 had mild neurological deficits.
Radiographic Outcome After Hospital Discharge
Follow-up MR images and conventional angiograms were available in 27 and 24 patients, respectively. The average length of radiographic follow-up was 80.2 months (range 9.4-257.1 months) with an average of 8.0 studies per patient (range 1-36 studies; Table 5 ).
On conventional angiography, 17 (40%) of 43 affected hemispheres demonstrated progression of the underlying moyamoya arteriopathy at the time of follow-up. New surgical collateral vessels were identified in 46 of 47 hemispheres. Of these hemispheres, 35 were graded using Based on a review of follow-up neuroimaging studies, 5 patients had a new infarction (in 6 hemispheres) after postoperative Day 7; 4 were diagnosed using MRI and 1 was diagnosed using CT. Among the patients treated using cranial irradiation, there was radiographic progression of moyamoya in 5 (36%) of 14 hemispheres and radiographic evidence of new stroke in 4 (25%) of 16 hemispheres compared with patients who did not undergo radiation, in whom 12 (41%) of 29 experienced progression and 2 (7%) of 30 suffered a stroke. During a combined 186 patient-years, the number of symptomatic patients was reduced from 78% to 5% after surgical intervention. Of note, 2 patients did experience strokes prior to postoperative Day 7 (both of whom underwent radiation treatment), which yields a total perioperative and postoperative stroke event rate of 4% per patient-year. Figure  2 demonstrates the stroke/event timeline for 16 patients from this series.
The presence of preoperative ischemic symptoms was predictive of a higher likelihood of delayed postoperative strokes. All 5 patients with radiographic evidence of a new stroke after postoperative Day 7 had a history of ischemic symptoms prior to surgical revascularization. In contrast, there appeared to be no significant difference in postoperative moyamoya disease progression in preoperatively asymptomatic patients (3 of 7, 43%) compared with symptomatic patients (14 of 36, 39%).
Untreated NF1-Related Moyamoya
There were 7 patients with NF1 and moyamoya who did not undergo pial synangiosis. Of these 7 patients, 2 had insufficient radiological data for review and we only included patients for whom imaging was visualized. One patient had glioblastoma with progression of the underlying tumor, and therefore revascularization was deferred; the patient subsequently died of underlying disease. Two other patients had symptomatic expansive brainstem lesions, 1 with a concurrent symptomatic optic pathway glioma and 1 with an extensive head and neck plexiform neurofibroma, each associated with worsening neurological status, and therefore surgery was deferred. The latter patient died of disease. Two patients were diagnosed with moyamoya disease incidentally. One patient elected not to proceed with surgery as this patient had already experienced a large infarct on the side contralateral to the hemisphere with more severe stenosis. The second patient also elected observation instead of proceeding with surgery. Both patients remain asymptomatic at 56.4 and 108.1 months, respectively.
Discussion
Children with NF1 manifest a wide spectrum of cerebrovascular abnormalities with an overall prevalence of approximately 2.5%, including narrowed or ectatic vessels, vascular stenoses, aneurysms, and moyamoya. 3, 13 The pathogenesis of moyamoya in the setting of NF1 remains unclear, although several hypotheses for its mechanism have been suggested. The NF1 gene is found on chromosome 17 and encodes for neurofibromin, which is expressed in endothelial and smooth-muscle cells of blood vessels.
3 Candidate pathogenic gene mutations for moyamoya have also been identified on chromosome 17, within the region of the NF1 gene.
1 A "second hit" to the normal NF1 allele within the vasculature has been demonstrated to result in the absence or altered function of neurofibromin within vascular endothelial and smooth- muscle cells, leading to increased proliferation and neovascularization. 6, 11 This "second hit" may be a sporadic mutation or secondary to damage to the vessel wall, including injury from cranial irradiation. This likely also increases the vulnerability of the cerebral vasculature to further injury from radiation or from compression or encasement by a tumor or mass, again promoting the development and progression of moyamoya syndrome. 2 Independent of the underlying pathophysiology, the arteriopathy observed in patients with NF1 has many similarities to nonsyndromic moyamoya. Whereas children with NF1 who develop moyamoya are 8 times more likely to be asymptomatic at the time of initial diagnosis than children with moyamoya who do not have NF1-presumably secondary to the surveillance scanning performed in the NF1 population, thus increasing the probability of discovering moyamoya as an incidental finding-the age at diagnosis for NF1 patients with moyamoya is comparable to the non-NF1 moyamoya group, at about 7 years old. 13, 20 Also similar to the non-NF1 population, there was a female preponderance in this series, with a female/male ratio of approximately 2:1. In many ways, our data demonstrate that the clinical, radiographic, and angiographic features of moyamoya in children with NF1 are otherwise comparable to primary moyamoya disease.
Clinically, for those patients with NF1 and moyamoya, the most common symptoms are attributable to cerebral ischemia, a finding identical to children with non-NF1 moyamoya.
14,15 Both NF1 and non-NF1 populations manifest unpredictable patterns of disease progression, which ultimately affects the majority of patients with the attendant risk of debilitating stroke. As noted in this series, while only 66% of patients were symptomatic at initial diagnosis, there was an increase in newly symptomatic children to 78% over time, reinforcing the hypothesis that moyamoya worsens over time in this group.
Radiographically, the MRI appearance of NF1-related and non-NF1 moyamoya are indistinguishable, with both groups showing FLAIR hyperintensity ("ivy sign") in underperfused cortex, a characteristic narrowing of the parent vessels in the anterior circulation of the brain, and in later stages, evidence of collateral formation and strokes in the same vascular distribution. 7, 21 On angiography, there are also identical findings between the 2 groups, with typical patterns of arteriopathy, collateral vessel development, and recruitment of alternative sources of blood flow. Interestingly, while one-third of patients in the entire cohort had unilateral disease, which is similar to our and other reports of non-NF1 moyamoya, if one excludes the patients with NF1 who had been treated with cranial irradiation, the percentage of unilateral cases increases to 50%. It is tempting to speculate that these children without prior radiation treatment, who were also less likely to be symptomatic prior to surgical revascularization, may represent a patient population at an early stage of the arteriopathy.
Children with NF1 tolerate operative intervention well, with a low complication rate, a clear radiographic response to indirect revascularization as demonstrated by angiographic ingrowth of new vessels, and, most importantly, a marked reduction in stroke risk. This decreased stroke risk is both durable over time and exists despite ongoing worsening of the underlying arteriopathy. Our data strongly support the use of pial synangiosis as a safe and effective method to protect against stroke, with a 27-fold reduction in risk of stroke for children with NF1 and moyamoya.
The timing of diagnosis relative to the timing of surgery in the NF1-moyamoya population is important. As noted above, many of the children in this series were diagnosed with moyamoya while asymptomatic or with lower Suzuki stages than comparable populations in non-NF1 moyamoya, presumably related to the screening studies performed for other NF1-related pathology. It has been established that clinical status at the time of moyamoya diagnosis and surgery is the most important determinant of overall outcome. 15 As such, there is a unique opportunity with these children to substantively reduce risk by treating them with early surgical intervention, prior to the onset of a debilitating stroke. This is also supported by the observations that many children developed clinical symptoms over time, and that radiographic progression occurred in 40% of patients; moreover, children who exhibited clinical symptoms preoperatively had the highest risks of perioperative complication. While clinicians need to exercise caution in confirming the diagnosis before committing a patient to surgery, and while the risks and benefits of each case must be determined individually, there is compelling evidence that reinforces the benefits of early diagnosis and justifies a proactive stance favoring early surgical revascularization.
Prior to the use of standard chemotherapeutic regimens for low-grade glioma, cranial irradiation was more frequently used as a treatment modality. In our cohort, 25% of patients were treated with cranial irradiation for symptomatic optic pathway gliomas. Subsequently, it has been shown that children with NF1 treated with radiation therapy are at increased risk for developing moyamoya syndrome and this risk is proportional to the radiation dose to the circle of Willis. 20 Moreover, children with NF1 are potentially at increased risk for neurocognitive compromise after treatment with radiation. 19 As concern for the injurious neurovascular and cognitive late effects of radiation have become more clarified, the trend is toward decreased use of cranial irradiation for younger children and, in particular, for children with NF1.
In our cohort, patients treated with cranial irradiation were more likely to be clinically symptomatic with evidence of prior ischemia both clinically and radiographically. In postoperative follow-up, all patients who were not previously treated with cranial irradiation demonstrated improved or stable clinical status, while those who were treated with cranial irradiation were more likely to have neurological deficits and had a higher complication rate. In addition, the perioperative stroke and complication rates were higher in patients who were treated with radiation despite similar rates of disease progression in patients with NF1 and moyamoya who did not undergo radiation treatment, suggesting that other factors independent of moyamoya may be contributing to the higher risk in this population.
This study is limited by its retrospective nature, rela-tively small number of patients, and variability in imaging follow-up duration over time. The inherent complexity of 2 contemporaneous conditions-NF1 and moya moyamake identifying some clinical symptoms difficult, and even more so when superimposed with 2 therapies and their attendant risks (surgery and radiation). Nonetheless, this series is, to our knowledge, the largest study of children with NF1 and moyamoya to date and provides insight into the natural history, response to surgical revascularization, and risk factors that influence the neurological outcome of this population.
Conclusions
The clinical, radiographic, and angiographic features of moyamoya syndrome in children with NF1 are largely comparable to primary moyamoya disease. In this population, the diagnosis of moyamoya syndrome may occur early in the disease process prior to any symptomatic evidence of cerebral ischemia as a consequence of imaging studies obtained for other manifestations of NF1. A history of cranial irradiation markedly increases the risk of developing symptomatic moyamoya and also increases the risk of perioperative complications. Patients who undergo surgical revascularization prior to developing neurological or ischemic symptoms demonstrate improved clinical outcomes, supporting the premise of screening this at-risk population. Surgical revascularization for children with NF1 appears safe and is protective against further ischemic and neurological damage, with a 27-fold reduction in stroke rate.
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